OncoMatch/Clinical Trials/NCT07248956
Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma
Is NCT07248956 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Finolizumab and Albumin-Bound Paclitaxel /nab-Paclitaxel for hypopharyngeal carcinoma.
Treatment: Finolizumab · Albumin-Bound Paclitaxel /nab-Paclitaxel · Cisplatin — This is a multi-center, randomized controlled, prospective clinical study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07248956 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III or IVA is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages